[Efficacy and safety of cetuximab+irinotecan for unresectable advanced or recurrent colorectal cancer].
In July 2008, cetuximab treatment for unresectable advanced or recurrent colorectal cancer was approved in Japan, but there have been few reports on this therapy in Japan. We retrospectively analyzed the efficacy and safety of cetuximab(Cmab)+irinotecan(CPT-11)for unresectable advanced or recurrent colorectal cancer from October 2008 to April 2010 at 5 centers in the Kanagawa region. The number of patients enrolled was 38, all of whom were treated after second-line therapy. The RR was 24%. DCR was 68%. TTF was 105 days and OS was 242 days. At 5 centers, Cmab+CPT-11 was an effective and safe treatment after second-line therapy.